Want to know what's happening next in healthcare?

MedCityNews is the leading online news source for the business of innovation in healthcare.


“I read MedCity because it captures the pulse of what's going on in healthcare innovation, a go to source. I also like how MedCity supports women in digital health.”

Dr. Charlene Ngamwajasat, @doctorcharlene, Physician and techie


Sign up for our daily newsletter


Biotechnology company acquires license for Alzheimer’s disease vaccine

April 9, 2012 11:58 am by | 0 Comments

A company has acquired a DNA vaccine for Alzheimer’s disease that is designed to trigger an immune response to the disease.

The vaccine, in preclinical development, differs from other Alzheimer’s vaccines under study in that it only contains a piece of the coding for the amyloid beta protein, a company statement said. Amyloid beta in the brain is believed to be linked to Alzheimer’s disease. With the vaccine, the antibodies bind onto and reduce amyloid beta.

Nuron Biotech in Exton, Pennsylvania licensed the vaccine from Texas biotechnology company Vitruvian BioMedical. Under the terms of the exclusive worldwide license, Nuron will be responsible for development and commercialization. The financial terms of the deal were not disclosed. The company is expected to advance the vaccine to the clinical stage next year.

The move comes as the latest expansion of its vaccine portfolio. Last month, it acquired the license for technology and product rights for a hepatitis B virus vaccine in the preclinical phase of development called Chimigen from Akshaya Bio.

Advertisement

Vaccines have been viewed as having potential to effectively combat Alzheimer’s disease and are being developed by companies such as Janssen Pharmaceuticals, in collaboration with Elan Corp. and Pfizer; GlaxoSmithKline (NYSE:GSK); and in a collaboration between Pfizer and  Johnson & Johnson, among others.

Alzheimer’s disease currently affects 5.4 million people.

Copyright 2014 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Stephanie Baum

By Stephanie Baum

Stephanie Baum is the East Coast Innovation Reporter for MedCityNews.com. She enjoys covering healthcare startups across health IT, drug development and medical devices and innovations deployed to improve medical care. She graduated from Franklin & Marshall College in Pennsylvania and has worked across radio, print and video. She's written for The Christian Science Monitor, Dow Jones & Co. and United Business Media.
Visit website | More posts by Author

0 comments

Hear the latest news first

Get our daily newsletter or follow us.

Advertisement